Twenty-four new mutations were identified in NPC1, one in NPC2 and three in SMPD1, confirming the diagnostic potential of 3β,5α,6β-triol for the lysosomal storage diseases NPC and NPB. Here, NPC2 is linked to nasopharyngeal carcinoma.